Sofinnova Partners Announces a New Investment From Its Medtech Acceleration Fund
Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today $5 million in seed funding for Endoron Medical (“Endoron”) to accelerate the development of the company’s endograft stapling solution for endovascular repair of abdominal aortic aneurysms (“AAA”). This is the third investment from its medtech acceleration fund, Sofinnova MD Start III.
Proceeds from the financing round will provide working capital to accelerate the full validation of the Endoron’s EndoStapling catheter-based solution. The funds will also be used to de-risk the regulatory strategy in preparation for the initial clinical experience, which will aim to establish safety, feasibility, and efficacy of the company’s patented endovascular suturing technology. In keeping with Sofinnova MD Start’s unique approach as a hands-on company builder, Cécile Dupont, Senior Associate and Program Director at Sofinnova Partners, will join the Endoron management team to bring greater operational and strategic support to accelerate the development of the company's highly disruptive technology.
Lukas Guenther, M.D., Partner at Sofinnova Partners and a key member of the Sofinnova MD Start III Fund, commented: “More than 400,000 new patients in the U.S. and Europe are diagnosed with AAA disease every year, with 42% presenting complex anatomies. These patients undergo endovascular repair, but still face long-term complications such as endograft migration, endoleaks, neck dilation, and consequently reinterventions. Endoron’s innovative technology has the potential to radically change the way we perform endovascular repair in AAA patients today, and to dramatically reduce complications and reinterventions.”
Ronit Harpaz, Co-Founder and Chief Executive Officer of Endoron, said: “The Sofinnova MD Start team are the go-to investors in the medtech domain and are also seasoned medtech entrepreneurs who bring a wealth of operational experience working in high-growth companies like ours. With their support, I am confident we will quickly reach key clinical and regulatory inflection points as we work to bring our EndoStapling technology to the clinic.”
Founded in 2019, Endoron Medical builds on an invention from Prof. Ron Karmeli (Hadassah Hospital, Jerusalem), who is co-founder and Chief Medical Officer of the Company.
Endoron’s technology has been developed to overcome the challenges associated with the sealing and fixation of endografts used for the minimally invasive repair of AAA in challenging anatomies and to avoid highly invasive, high-mortality open surgery, which is still being used in that case.
The Endoron solution is meant to secure an endograft's fixation and to improve sealing mechanisms. In addition, the stapling mechanisms developed by Endoron can be used to repair endovascular grafts that have migrated away from the implant site and have developed endoleaks. In such cases, augmented fixation and sealing is required to regain or maintain effective aneurysm exclusion.
The Sofinnova MD Start team is the only medtech accelerator in Europe and is comprised of seasoned medtech entrepreneurs and investors with extensive experience in high-growth early-stage medical device companies, and a successful track record of catalyzing innovative technology from conception to the clinic. The fund has made two other investments to date: Gradient Denervation Technologies and Moon Surgical.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply-established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: www.sofinnovapartners.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Head of Communications, Sofinnova Partners
firstname.lastname@example.org +33 (0) 6 47 71 38 11
+1 212 223 0561
+33 (0) 6 03 35 92 05
Havas PR Milan
Marco Fusco email@example.com
+39 (0) 345 6538145
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cloud Service Provider Bulutistan Selects Inspur Information to Upgrade Its Cloud Infrastructure26.1.2022 11:04:00 EET | Press release
Inspur Information, a leading IT infrastructure solutions provider, today announced it was selected by Bulutistan, the leading cloud service provider in Turkey and a top 5 provider in the EMEA region, to upgrade the company’s cloud infrastructure. Bulutistan faces rapid growth in its public cloud services that cannot be met by traditional cloud computing architecture. Inspur Information’s hyper-converged solution based on Inspur’s NF5280M5 server provides the extreme scalability Bulutistan requires in addition to a 30% reduction in operational costs. The three-tier architecture of traditional data centers (computing, storage, and network) is stable and reliable, but it is difficult to expand and requires complex equipment and that is time consuming and difficult to manage. It is not suitable for the next-generation data center cloudification that Bulutistan requires. Instead, the company needed a pooled IT infrastructure platform with maximum capacity and scalability that is also effic
Citi to Transform EMEA Headquarters in Major London Refurbishment26.1.2022 08:30:00 EET | Press release
Citi today announced its intent to transform its London headquarters, home to its UK and EMEA (Europe, Middle East and Africa) operations. The refurbishment of the iconic Citi Tower in Canary Wharf will create a stunning workplace for the future, incorporating the latest technology and the highest standards of environmental design. With flexible work and collaboration spaces, alongside well-being zones for employees, the transformation of Citi Tower represents Citi’s enduring commitment to its people, to London, and to delivering excellence for its clients around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125006049/en/ Conceptual image Citi Tower Interior (Graphic: Business Wire) “Our aim is to create an environmentally sustainable, innovative and exciting place to work, incorporating modern design, state-of-the-art technology, and best practices in employee and client spaces,” said David Livingstone, Citi’
Vending Machines International Secures SGD 135 Million Capital Commitment From Global Emerging Markets (GEM) as Company Seeks to Go Public26.1.2022 07:02:00 EET | Press release
Vending Machines International (VMI), today announced a SGD 135 Million capital commitment from GEM Global Yield LLC SCS ("GGY"), the Luxembourg-based private alternative investment vehicle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125006251/en/ (Photo: Business Wire) Under the agreement, GGY will provide VMI with a Share Subscription Facility of up to SGD 135 million for a 36-month period following a public listing of VMI’s common stock. VMI will control the timing and maximum amount of drawdowns under this facility and has no minimum drawdown obligation. “VMI is very pleased to be selected by the GEM Group to receive this investment. It is a credit to the GEM management that they very quickly grasped that the world is moving to remove single use plastics from the supply chain. VMI is extremely well placed to take advantage of this transition. With GEM’s funds to strengthen the VMI balance sheet VMI will be able to
Private Messaging App Launches on Quantum Resistant, Decentralized xx network25.1.2022 18:30:00 EET | Press release
The world’s first quantum-resistant messaging app, xx messenger , launched on the xx network today. xx messenger allows users to communicate in real time through hundreds of decentralized nodes operating worldwide. The app is available for download on IOS and Android, features group chat as well as photo and audio sharing, and designed for easy use and switching to from legacy messaging apps. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125005773/en/ David Chaum (Photo: Business Wire) Unlike existing messaging apps, xx messenger uses quantum-resistant cryptography to protect message content from decoding and cMix software to obfuscate or shred metadata—information about who sends, when they send, where they send from, and who receives. Randomly selected teams of xx nodes encrypt anonymity sets of 1,000 messages, which are then repeatedly shuffled and have also been encrypted using quantum-resistant cryptography. Informa
MDSLink Makes MaGiC™25.1.2022 18:00:00 EET | Press release
In response to the fiber buildout worldwide, and the continuous demand for reliable bandwidth, MDSLink, Inc. is now offering MaGiC™, a very high-performance, networking module that uses the existing coax. MaGiC is a cost-effective, easy-to-install module that extends the fiber footprint found in MDUs, single-family homes, hotels/resorts and offices or any building with existing coax. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220125005534/en/ MaGiC Small Form Factor Pluggable (Photo: Business Wire) MaGiC-SFP 2.5™ (Multi-Gigabit Coax Small Form-factor Pluggable) provides up to 2.5 Gbps—symmetrical—actual data rates when plugged into an Ethernet network (SFP/SFP+ port). Applications: - Last 100-meter distribution using existing, in-building coax. - Wireless AP backhaul in-premise. Supplements in-home Wi-Fi® mesh networks using fail safe, wireline backhaul between devices. Using WAPs with SFP-ports, operators can backhaul t
Kroll Unifies Brand to Reflect Strategic Growth and Vision25.1.2022 18:00:00 EET | Press release
Kroll, the leading provider of data, technology and insights related to risk, governance and growth, announces today the completion of its transition to a unified brand. Through its combined capabilities, Kroll is uniquely positioned to help clients stay ahead of complex business demands and opportunities across dynamic regulatory, economic and risk environments. “Our brand unification is a necessary evolution to deliver superior client service and meet and anticipate our clients’ increasingly complex and interconnected needs,” said Jacob Silverman, Chief Executive Officer of Kroll, “This marks the beginning of a new chapter for Kroll that reflects our market leadership across borders and disciplines, and embraces our proprietary data, technology and insights to create value and impact for our clients and communities.” Last year, the Company announced plans to unify its business following significant organic growth and strategic acquisitions. Kroll’s full suite of solutions now span se
Dr. Philip Krause to Provide Strategic Advice to Adjuvance25.1.2022 17:35:00 EET | Press release
Adjuvance Technologies Inc., a privately-held clinical-stage biopharmaceutical company developing next generation saponin adjuvants and vaccines for infectious disease and immuno-oncology, today announced that Philip Krause, MD, will take on a strategic consulting role with the organization as it advances its vaccine development portfolio. Dr. Krause recently served as the Deputy Director, Office of Vaccines Research and Review of the US Food and Drug Administration (FDA) Center for Biologics Evaluation and Research. “The deep scientific, regulatory and vaccine development experience that Phil brings to Adjuvance will be instrumental in efficiently developing our shingles vaccine candidate and our pipeline anchored on the next-generation saponin adjuvant TQL-1055,” noted Dr. Tyler Martin, Adjuvance CEO, President and Chairman. “I am thrilled to enhance the company’s expertise with such a well-respected scientist.” Dr. Krause previously had a 30-year career in the FDA where he made majo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom